GB9513074D0 - Novel anigen - Google Patents

Novel anigen

Info

Publication number
GB9513074D0
GB9513074D0 GBGB9513074.6A GB9513074A GB9513074D0 GB 9513074 D0 GB9513074 D0 GB 9513074D0 GB 9513074 A GB9513074 A GB 9513074A GB 9513074 D0 GB9513074 D0 GB 9513074D0
Authority
GB
United Kingdom
Prior art keywords
methods
influenzae
novel
protein
anigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9513074.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortecs Ltd
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Priority to GBGB9513074.6A priority Critical patent/GB9513074D0/en
Publication of GB9513074D0 publication Critical patent/GB9513074D0/en
Priority to RU98101249/13A priority patent/RU2221045C2/ru
Priority to DE69635783T priority patent/DE69635783T2/de
Priority to ES96920996T priority patent/ES2259443T3/es
Priority to CA002225405A priority patent/CA2225405A1/en
Priority to EP96920996A priority patent/EP0835313B1/en
Priority to AU62363/96A priority patent/AU708061B2/en
Priority to AT96920996T priority patent/ATE317013T1/de
Priority to ZA9605482A priority patent/ZA965482B/xx
Priority to JP9504247A priority patent/JPH11510373A/ja
Priority to KR1019970709739A priority patent/KR19990028423A/ko
Priority to CNB961951389A priority patent/CN1144875C/zh
Priority to NZ311120A priority patent/NZ311120A/en
Priority to PCT/GB1996/001549 priority patent/WO1997001638A1/en
Priority to TW085111139A priority patent/TW457247B/zh
Priority to MX9710412A priority patent/MX9710412A/es
Priority to US08/996,408 priority patent/US6245338B1/en
Priority to NO976119A priority patent/NO976119L/no
Priority to US09/310,847 priority patent/US6254875B1/en
Priority to US09/310,845 priority patent/US6284477B1/en
Priority to US09/548,023 priority patent/US6313281B1/en
Priority to JP2008226372A priority patent/JP2009034107A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
GBGB9513074.6A 1995-06-27 1995-06-27 Novel anigen Pending GB9513074D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GBGB9513074.6A GB9513074D0 (en) 1995-06-27 1995-06-27 Novel anigen
PCT/GB1996/001549 WO1997001638A1 (en) 1995-06-27 1996-06-27 Omp26 antigen from haemophilus influenzae
KR1019970709739A KR19990028423A (ko) 1995-06-27 1996-06-27 해모필러스 인플루엔자로부터 유래한 오엠피26 항원
NZ311120A NZ311120A (en) 1995-06-27 1996-06-27 Vaccine containing the omp26 antigen from haemophilus influenzae
ES96920996T ES2259443T3 (es) 1995-06-27 1996-06-27 Antigeno omp26 de la bacteria haemophilus influenzae.
CA002225405A CA2225405A1 (en) 1995-06-27 1996-06-27 Omp26 antigen from haemophilus influenzae
EP96920996A EP0835313B1 (en) 1995-06-27 1996-06-27 Omp26 antigen from haemophilus influenzae
AU62363/96A AU708061B2 (en) 1995-06-27 1996-06-27 OMP26 antigen from haemophilus influenzae
AT96920996T ATE317013T1 (de) 1995-06-27 1996-06-27 Antigen omp26 aus haemophilus influenzae
ZA9605482A ZA965482B (en) 1995-06-27 1996-06-27 Novel antigen.
JP9504247A JPH11510373A (ja) 1995-06-27 1996-06-27 インフルエンザ菌由来のｏｍｐ２６抗原
RU98101249/13A RU2221045C2 (ru) 1995-06-27 1996-06-27 ОМР26 АНТИГЕН Haemophilus influenzae, КОДИРУЮЩАЯ ЕГО НК И ЕГО ИСПОЛЬЗОВАНИЕ
CNB961951389A CN1144875C (zh) 1995-06-27 1996-06-27 流感嗜血杆菌的omp26抗原
DE69635783T DE69635783T2 (de) 1995-06-27 1996-06-27 Antigen omp26 aus haemophilus influenzae
TW085111139A TW457247B (en) 1995-06-27 1996-09-12 Novel antigen
MX9710412A MX9710412A (es) 1995-06-27 1997-12-18 Antigeno omp26 de haemophilus influenzae.
US08/996,408 US6245338B1 (en) 1995-06-27 1997-12-22 OMP26 antigen from Haemophilus influenzae
NO976119A NO976119L (no) 1995-06-27 1997-12-29 OMP26-antigen fra Haemophilus influenzae
US09/310,847 US6254875B1 (en) 1995-06-27 1999-05-13 Methods for use of OMP26 from Haemophilus influenzae
US09/310,845 US6284477B1 (en) 1995-06-27 1999-05-13 Diagnostic method of use of OMP26 antigen from Haemophilus influenzae
US09/548,023 US6313281B1 (en) 1995-06-27 2000-04-12 Nucleic acid encoding OMP26 antigen from Haemophilus influenzae
JP2008226372A JP2009034107A (ja) 1995-06-27 2008-09-03 インフルエンザ菌由来のｏｍｐ２６抗原

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9513074.6A GB9513074D0 (en) 1995-06-27 1995-06-27 Novel anigen

Publications (1)

Publication Number Publication Date
GB9513074D0 true GB9513074D0 (en) 1995-08-30

Family

ID=10776746

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9513074.6A Pending GB9513074D0 (en) 1995-06-27 1995-06-27 Novel anigen

Country Status (18)

Country Link
US (4) US6245338B1 (https=)
EP (1) EP0835313B1 (https=)
JP (2) JPH11510373A (https=)
KR (1) KR19990028423A (https=)
CN (1) CN1144875C (https=)
AT (1) ATE317013T1 (https=)
AU (1) AU708061B2 (https=)
CA (1) CA2225405A1 (https=)
DE (1) DE69635783T2 (https=)
ES (1) ES2259443T3 (https=)
GB (1) GB9513074D0 (https=)
MX (1) MX9710412A (https=)
NO (1) NO976119L (https=)
NZ (1) NZ311120A (https=)
RU (1) RU2221045C2 (https=)
TW (1) TW457247B (https=)
WO (1) WO1997001638A1 (https=)
ZA (1) ZA965482B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468765B1 (en) 1995-04-21 2002-10-22 Human Genome Sciences, Inc. Selected Haemophilus influenzae Rd polynucleotides and polypeptides
US6355450B1 (en) 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
GB9904183D0 (en) * 1999-02-24 1999-04-14 Smithkline Beecham Biolog Novel compounds
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP2088197B8 (en) * 2000-10-02 2016-07-20 ID Biomedical Corporation of Quebec Haemophilus influenzae antigens and corresponding DNA fragments
RU2185191C1 (ru) * 2001-02-01 2002-07-20 Ростовский научно-исследовательский институт микробиологии и паразитологии Способ получения антигенного препарата haemophilus influenzae типа b (hib)
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP1524991A1 (en) 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
CN101687025A (zh) * 2005-03-30 2010-03-31 诺华疫苗和诊断公司 B型流感嗜血杆菌
CN100357318C (zh) * 2005-10-11 2007-12-26 中山大学 美人鱼发光杆菌外膜蛋白w和编码序列及其制备方法和应用
KR100743604B1 (ko) * 2005-12-05 2007-07-27 볼보 컨스트럭션 이키프먼트 홀딩 스웨덴 에이비 차량용 머플러 구조
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PL1973564T3 (pl) 2005-12-22 2017-04-28 Glaxosmithkline Biologicals S.A. Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
AU2007206114B2 (en) 2006-01-17 2013-01-24 Arne Forsgren A novel surface exposed Haemophilus influenzae protein (protein E; pE)
SI2167121T1 (sl) 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
EP2544714A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
US20130156803A1 (en) 2011-06-04 2013-06-20 Rochester General Hospital Research Institute Compositions and methods related to p6
CN104321078A (zh) * 2012-04-26 2015-01-28 诺华股份有限公司 抗原和抗原组合
CN104370997B (zh) * 2014-09-24 2018-07-31 陈辉 去除生物制品中细菌内毒素的试剂盒、方法及其生物制品的制备方法
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CA3063954A1 (en) 2017-05-30 2018-12-06 Glaxosmithline Biologicals S.A. Methods for manufacturing an adjuvant
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033600T2 (de) * 1989-03-09 2001-04-05 American Cyanamid Co., Madison Verfahren zur Isolierung von Haemopnilus influenzae Protein-E
GB8924473D0 (en) * 1989-10-31 1989-12-20 Connaught Lab Outer membrane protein p1 and peptides of haemophilus influenzae b
GB9224584D0 (en) * 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases

Also Published As

Publication number Publication date
AU6236396A (en) 1997-01-30
RU2221045C2 (ru) 2004-01-10
TW457247B (en) 2001-10-01
DE69635783T2 (de) 2006-11-02
WO1997001638A1 (en) 1997-01-16
JPH11510373A (ja) 1999-09-14
KR19990028423A (ko) 1999-04-15
US6284477B1 (en) 2001-09-04
AU708061B2 (en) 1999-07-29
CN1144875C (zh) 2004-04-07
JP2009034107A (ja) 2009-02-19
NO976119D0 (no) 1997-12-29
EP0835313A1 (en) 1998-04-15
US6313281B1 (en) 2001-11-06
US6254875B1 (en) 2001-07-03
EP0835313B1 (en) 2006-02-01
ES2259443T3 (es) 2006-10-01
DE69635783D1 (de) 2006-04-13
CN1189186A (zh) 1998-07-29
MX9710412A (es) 1998-07-31
NO976119L (no) 1998-02-26
NZ311120A (en) 1999-10-28
ATE317013T1 (de) 2006-02-15
CA2225405A1 (en) 1997-01-16
US6245338B1 (en) 2001-06-12
ZA965482B (en) 1997-12-29

Similar Documents

Publication Publication Date Title
GB9513074D0 (en) Novel anigen
NO980883L (no) Forbindelser og fremgangsmÕter for immunterapi og diagnose av tuberkulose
WO2000039299A3 (en) Streptococcus antigens
WO1999042588A3 (en) Group b streptococcus antigens
GB9224584D0 (en) Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
NO20006191L (no) Vaksine
WO2001098460A3 (en) Fusion proteins of mycobacterium tuberculosis
NZ500540A (en) Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae
AU1463097A (en) Helicobacter pylori bacterioferritin
DK0680765T3 (da) Vaccine til ikke-typebestemmelig Haemophilus influenzae-stamme
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
IL117151A0 (en) Novel antigen
AU2001239262A1 (en) Haemophilus influenza outer membrane protein and use thereof in vaccination
WO1999002554A3 (en) Human herpesvirus-7 diagnostic and immunologic reagents and use thereof
EP1950302A3 (en) Streptococcus antigens